环硅酸锆钠可提高高钾血症患者的血清碳酸氢盐浓度:三项随机、多剂量、安慰剂对照试验的探索性分析
本文基于三项随机安慰剂对照3期试验(ZS-003、HARMONIZE、HARMONIZE-Global)的探索性分析,评估环硅酸锆钠(SZC)对高钾血症患者血清碳酸氢盐的影响。结果显示,SZC每日三次治疗48小时内出现剂量依赖性的血清碳酸氢盐升高(0.3-1.5 mmol/L),且不依赖CKD分期;维持治疗期间该效应持续,最高维持剂量下血清碳酸氢盐<22 mmol/L的患者比例显著下降。路径分析提示SZC对血清碳酸氢盐的影响与血清尿素下降相关。
要点
- SZC治疗48小时内剂量依赖性升高血清碳酸氢盐0.3-1.5 mmol/L。
- 血清碳酸氢盐升高不依赖CKD分期,维持治疗期间持续存在。
- 最高维持剂量下血清碳酸氢盐<22 mmol/L的患者比例显著降低。
核心结论
- SZC可提高高钾血症患者的血清碳酸氢盐浓度,并减少血清碳酸氢盐<22 mmol/L的患者比例。
研究设计与样本
- 三项随机、多剂量、安慰剂对照3期试验的探索性分析,共纳入ZS-003(n=753)、HARMONIZE(n=258)和HARMONIZE-Global(n=267)的高钾血症患者。
- 所有研究中,患者先接受SZC ≤10 g 每日三次治疗48小时以纠正高钾血症,达到正常血钾者随后随机接受SZC每日一次维持治疗或安慰剂,最长29天。
主要发现
- ZS-003中,SZC每日三次治疗48小时内血清碳酸氢盐较基线平均升高0.3至1.5 mmol/L(所有P < 0.05),且不依赖CKD分期。
- HARMONIZE和HARMONIZE-Global中类似的急性升高在29天内维持。
- 最高SZC维持剂量下,HARMONIZE中血清碳酸氢盐<22 mmol/L的患者比例从基线39.4%降至29天时4.9%(P = 0.005),HARMONIZE-Global中从87.9%降至70.1%(P = 0.006)。
- 路径分析显示,血清尿素下降(而非血清钾或尿pH变化)与SZC对血清碳酸氢盐的影响相关。
临床怎么用
- 对于高钾血症患者,SZC在降钾的同时可能改善血清碳酸氢盐水平,尤其适用于合并代谢性酸中毒风险者。
- 治疗期间可监测血清碳酸氢盐以评估SZC对酸碱平衡的潜在获益。
局限性
- 本研究为探索性分析,结果需前瞻性研究验证。
- 原文未报告部分亚组的具体样本量及置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium zirconium cyclosilicate (SZC) binds potassium and ammonium in the gastrointestinal tract. In addition to serum potassium reduction, Phase 2 trial data have shown increased serum bicarbonate with SZC, which may be clinically beneficial because maintaining serum bicarbonate ≥22 mmol/L preserves kidney function. This exploratory analysis examined serum bicarbonate and urea, and urine pH data from three SZC randomized, placebo-controlled Phase 3 studies among patients with hyperkalaemia [ZS-003 (n = 753), HARMONIZE (n = 258) and HARMONIZE-Global (n = 267)]. METHODS: In all studies, patients received ≤10 g SZC 3 times daily (TID) for 48 h to correct hyperkalaemia, followed by randomization to maintenance therapy with SZC once daily (QD) versus placebo for ≤29 days among those achieving normokalaemia. RESULTS: Significant dose-dependent mean serum bicarbonate increases from baseline of 0.3 to 1.5 mmol/L occurred within 48 h of SZC TID in ZS-003 (all P < 0.05), which occurred regardless of chronic kidney disease (CKD) stage. Similar acute increases in HARMONIZE and HARMONIZE-Global were maintained over 29 days. With highest SZC maintenance doses, patient proportions with serum bicarbonate <22 mmol/L fell from 39.4% at baseline to 4.9% at 29 days (P = 0.005) in HARMONIZE and from 87.9% to 70.1%, (P = 0.006) in HARMONIZE-Global. Path analyses demonstrated that serum urea decreases (but not serum potassium or urine pH changes) were associated with SZC effects on serum bicarbonate. CONCLUSIONS: SZC increased serum bicarbonate concentrations and reduced patient proportions with serum bicarbonate <22 mmol/L, likely due to SZC-binding of gastrointestinal ammonium. These SZC-induced serum bicarbonate increases occurred regardless of CKD stage and were sustained during ongoing maintenance therapy.
引用
- Roger SD, Spinowitz BS, Lerma EV, et al. Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials. Nephrol Dial Transplant. 2021. PMID: 32588050. doi:10.1093/ndt/gfaa158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。